Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alrizomadlin and Pembrolizumab in Advanced Solid Tumors
NCT03611868Phase 2Active, not recruiting
- Sponsor
- Ascentage Pharma
- Start
- Aug 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of alrizomadlin in melanoma, solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and 3 more (3 arms), sponsored by Ascentage Pharma. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Phase II Dose at 21 days and 1 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
alrizomadlin
03
Conditions
melanomasolid tumor (advanced stage)non-small cell lung cancer (NSCLC)Liposarcomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03611868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611868.